The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to our portfolio company PCI Biotech. This is a major regulatory milestone for the development of the company´s lead product candidate named fimaporfin for the treatment of patients suffering from bile duct cancer. This patient population has no approved treatment alternatives today […]
Radforsk co-hosted three cancer-related events during Oslo Innovation Week and Forskningsdagene. If you missed out, you may watch them now. Together with our partners the Norwegian Cancer Society, Oslo Cancer Cluster, IBM Norway, Cancer Research UK, Norway Health Tech and EAT, we hosted these events. We had great audiences during our three events on the 27th and […]
The progress especially applies for the fimaCHEM programme , with early promising signs of effect in Phase I in treatment of bilde duct cancer.
Reports significant progress, both financially and clinically, in second half 2017 report.
We arrange three seminars during Oslo Innovation Week and Forskningsdagene.
Q2 report shows significant progress in the US market
Second quarter report shows continued solid operational progress.
Jónas Einarsson, administrerende direktør i Radiumhospitalets Forskningsstiftelse skal delta på tre debatter under Arendalsuka. Det er viktige og aktuelle temaer som kliniske studier, et todelt helsevesen og norske kreftpasienters tilgang til den best mulige kreftbehandling, som Einarsson skal være med å debattere. Hør Einarsson her i Arendal: Sustainable, Innovative Healthcare Tirsdag 15. aug kl 15 […]
Our portfolio company Nordic Nanovector shows continued progress in clinical development programmes with Betalutin® in their first quarter 2017 presentation. Luigi Costa, CEO of Nordic Nanovector, comments: “In the first quarter of 2017 we continued the positive momentum of 2016. I am pleased to report the excellent progress Nordic Nanovector is making to advance its clinical […]